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Abstract
Background: Fabry’s disease is a rare X-linked genetic disorder characterized by reduced levels of the α-
galactosidase A enzyme. It may present with a cardiac phenotype resembling hypertrophic cardiomyopathy.
However, as a specific enzyme replacement therapy is available, it remains an important differential diagnoses in
patients presenting with cardiac hypertrophy. In boys, onset has been reported in early childhood with complaints
initially comprising neuropathic pain, reduced sweat production, and gastrointestinal symptoms. Later the cardiac,
renal, and central nervous systems may become affected. Female mutation carriers may remain asymptomatic or
present at a later age with varying symptoms and clinical manifestations due to random inactivation of the X
chromosome in different organs.
Case presentation: Here we present a case of Fabry’s disease diagnosed in the daughter of an elderly, Caucasian
woman (81 years old) with late-onset cardiac conduction disease and heart failure. We discuss the implications of
cascade screening relatives of elderly probands.
Conclusions: Irrespective of the patient’s age, physicians must be on the lookout for phenocopies when identifying
patients with possibly inheritable cardiomyopathies. The specific – precise – diagnosis may be crucial for the
patient as well as the relatives.
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Background
Fabry’s disease (FD) is a rare X-linked lysosomal stor-
age disease with an estimated prevalence of 1:117,000
[1]. Numerous private mutations in the gene encoding
for the α-galactosidase A enzyme (GLA) have been
associated with the condition. The mutations result in
defect catabolism of glycosphingolipid resulting from
lowered activity of the lysosomal α-galactosidase A
enzyme. Affected individuals accumulate glycosphin-
golipids in the lysosomes and cytoplasm of cells
throughout the body [2]. Typical early symptoms in-
clude temperature-provoked pain in the extremities,
reduced ability to sweat (hypo- or anhydrosis), nau-
sea, and abdominal pain. Later arterial hypertension,
left ventricular (LV) hypertrophy, heart failure, con-
duction abnormalities, renal insufficiency, and symp-
toms from the central nervous system may present
(stroke, tinnitus, and hearing impairment). The pre-
senting symptoms usually manifest during childhood
but can be delayed especially in heterozygous cases.
Patients with FD may gradually develop terminal
renal insufficiency and severe cardiac dysfunction and
their life expectancy is reduced by 20 and 15 years in
males and females, respectively [2]. A cardiac variant,
characterized by only – or mainly – cardiac involve-
ment has been reported [3]. This case report reminds
us that Fabry’s disease can cause familial cardiomyop-
athy that may present late and/or in a milder form in
female mutation carriers.
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Case presentation
The mother (patient 1)
A 74-year-old Caucasian woman was referred due to grad-
ual worsening of dyspnea with aggravation during a recent
skiing trip. Her previous medical history included mild
asthma and osteoporosis, surgical treatment for rectal can-
cer 30 years prior to presentation, and an evaluation for
dizziness 4 years previously when a computed tomography
scan of the cerebrum was without any positive findings.
The patient denied palpitations but reported occasional
retrosternal oppression and two incidences of near syn-
cope. Aside from age, she had no risk factors for ischemic
heart disease.
A physical examination revealed an arterial blood pres-
sure of 132/70 mmHg, a heart rate of 40 bpm, normal oxy-
gen saturation, normal body temperature, and no dyspnea
at rest. Further examination revealed jugular vein distension
while sitting upright in bed and a discreet systolic murmur.
The electrocardiogram (ECG) showed atrial fibrillation and
complete atrioventricular block. Blood tests were normal
except from consistent low-grade elevation of the cardiac
troponin I. An echocardiogram showed severely dilated left
atria, mild mitral regurgitation, borderline dilated LV with
near-normal systolic function and no hypertrophy. Acute
coronary syndrome was not considered present and our pa-
tient underwent an uneventful implantation of a dual-
chamber pacemaker (DDDR). Following discharge, the pa-
tient was followed by her private cardiologist. It was later
noted that cardiac hypertrophy and a slight decrease in LV
ejection fraction had developed, the latter possibly consid-
ered secondary to cardiac pacing.
Over the next 5 years, our patient was repeatedly admitted
to the emergency department with dyspnea. At our institu-
tion, the echocardiogram was repeated when our patient, at
the age of 78 years, was admitted with severe respiratory dis-
tress interpreted as pulmonary edema. Her LV ejection frac-
tion had decreased to 15% (Fig. 1a). A subsequent coronary
angiogram was without any coronary artery lesions and she
was diagnosed with non-ischemic, non-valvular dilated car-
diomyopathy (DCM). Subsequently, our patient’s pacemaker
was upgraded to a biventricular pacemaker without anti-
tachycardia pacing or defibrillator function. At age 81 years,
our patient suffered several episodes of ventricular tachyar-
rhythmias and died within days. During hospitalizations
Fig. 1 Echocardiograms from the two patients presented. Panel a, parasternal images from the asymptomatic daughter. The interventricular
septum measured 15 mm (reference < 11 mm). Panel b, the echocardiogram from the mother aged 81 years. The scan demonstrates a dilated
left ventricle (LVIDd 46 mm/m2, reference < 32 mm/m2) and severe systolic heart failure (left ventricular ejection fraction estimated to 15%). Panel
c, cardiac magnetic resonance imaging of the daughter. The cardiac magnetic resonance scan demonstrated preserved systolic function and mild
left ventricular hypertrophy (143 g/m2, normal range 69–141 g/m2). The cardiac magnetic resonance also demonstrated late gadolinium
hyperenhancement in inferolateral left ventricular myocardial segments, that is, in a pattern highly suspicious of a cardiac phenotype with
Fabry’s disease
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from the pacemaker insertion, renal function had declined
to an estimated glomerular filtration rate of 30 ml/min/m2
(normal range > 60 ml/min/m2).
The daughter (patient 2)
The daughter of patient 1 was referred for evaluation from
her general practitioner (GP). She had contacted her GP
because of her mother’s death asking if her mother’s car-
diac condition might have been an inherited disorder,
which might indicate a risk for herself. She was 52 years
old, worked full-time and was physically active without
limitations. Her medical history was unremarkable except
for well-controlled hypertension. Blood samples showed
elevated cardiac troponins (troponin I was 121 ng/L,
normal range < 40 ng/L) and an ECG suggested LV hyper-
trophy. These test results prompted referral to our clinic.
Her blood pressure was 142/98 mmHg, heart rate was 57
bpm. An echocardiogram showed hypertrophy (15 mm) of
the interventricular septum without LV outflow tract ob-
struction. No other pathologies were identified on the echo-
cardiogram (Fig. 1b). The LV ejection fraction was normal.
Further blood work demonstrated a phosphocreatinine kin-
ase myocardial band (CK-MB) of 5.9 μg/L (normal range <
7 μg/L), slightly elevated lactate dehydrogenase (212; U/L;
normal range 105–205 U/L) and B-type natriuretic peptide
(616 ng/L; normal range < 450 ng/L). Creatinine, elec-
trolytes, thyroid hormones, hemoglobin, cholesterol, and
hemoglobin A1c (HgbA1c) were all normal. A 24-hour
blood pressure monitoring showed a mean of 116/80
mmHg, and a cardiac stress test was performed without eli-
citing symptoms or signs of ischemia and a normal blood
pressure response was recorded during exercise. A 24-hour
ambulatory blood pressure test confirmed that the patient’s
hypertension was well-controlled (average 116/80 mmHg)
and a 24-h ambulatory ECG monitoring did not identify ar-
rhythmias. We compared this patient’s ECG with her
mother’s (Fig. 2) and noted that the alterations were quite
similar, and for this reason an inheritable cardiac condition
was suspected.
Following information from our patient, genetic testing,
and a cardiac magnetic resonance (CMR) imaging scan
was ordered (Fig. 1c). The genetic testing identified a pre-
viously reported FD causing mutation in the coding part
of the GLA gene (c.901C>T,p.R301*). CMR confirmed LV
hypertrophy and demonstrated late gadolinium hyperen-
hancement in inferolateral segments in a mid-myocardial
location. The scan was in agreement with a diagnosis of
FD, and our patient was referred to a tertiary center for
evaluation for treatment with enzyme replacement ther-
apy (ERT).
Discussion
In the family described here, the sudden cardiac death
(SCD) of the proband at age 81 years, prompted her
daughter to request cardiac testing, leading to the diagnosis
of Fabry’s disease. Evaluation of relatives (cascade screening)
for familial cardiac diseases is straightforward when a well-
defined phenotype is present in the proband. However,
screening of relatives to SCD victims has a low yield that
decreases with the age of the index case [4–6]. Therefore,
the national Danish guidelines for SCD do not recommend
cascade screening in relatives of older probands (>50 (−60)
years) [7, 8].
In brief, this report describes a mother and daughter with
structurally similar cardiac phenotypes. The mother pre-
sented with complete heart block followed by development
of LV hypertrophy and finally by LV systolic failure. Had
the patients’ completely asymptomatic daughter inquired
whether we would recommend cascade screening and ini-
tiate clinical testing of her, current guidelines would have
discouraged us from doing so [7]. However, investigations
had already been performed and were abnormal. Thus, the
ECG and echocardiogram demonstrated LV hypertrophy
that indicated further testing on the suspicion of hyper-
trophic cardiomyopathy (HCM).
Fig. 2 Electrocardiograms from the two patients presented. Panel
a, electrocardiogram from the 52-year-old asymptomatic daughter.
Panel b and c, electrocardiograms from the proband at age 79 and
81 years, respectively
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HCM is not uncommon (estimated prevalence is 1:500)
[9], and its diagnosis should prompt the search for the spe-
cific etiology as specific therapy is available for certain
phenocopies, that is, Fabry’s disease and carnitine trans-
porter defect. In general, management in HCM consists of
genetic counseling, symptomatic relief in cases with LV out-
flow obstruction, stroke prevention in patients with concur-
rent atrial fibrillation, and monitoring of risk factors for
SCD with recommendations of prophylactic implantable
cardioverter-defibrillator (ICD) therapy in high-risk patients
[10]. However, a number of phenocopies, acquired as well
as genetic, may mimic HCM but – in contrast to gen-
etic HCM – may be amenable to specific therapies. Most
commonly, such phenocopies would be significant LV
hypertrophy caused by poorly controlled hypertension,
aortic stenosis or athlete’s heart. More rarely, obesity,
hemochromatosis, and storage or metabolic diseases may
elicit cardiac hypertrophy. In the family presented here,
FD was one of several differential diagnoses as the proband
had presented with conduction abnormalities, myocar-
dial hypertrophy with progression to a dilated cardio-
myopathy phenotype with concurrent development of
renal insufficiency.
Whereas males with FD generally present in childhood,
women often present later and with milder and more vari-
able symptoms [2]. Except for admittance due to stomach
pains and late-presenting kidney failure after the cardiac
arrest in patient 1, none of the non-cardiac manifestations
of FD were reported by either patient. Another diagnostic
clue may be a short PR interval in the ECG of patients
with FD. However, this feature was not seen in either case
presented here. Both mother and daughter showed con-
tinuously elevated cardiac troponins, which has previously
been reported in FD cohorts and seems to be correlated
to cardiac hyperenhancement as assessed by late gadolin-
ium CMR [11]. This specific pattern may be useful in dif-
ferentiating FD from HCM and other storage diseases
[12]. CMR with late gadolinium demonstrates specific
findings differentiating FD from HCM [13]. When man-
aging families with possibly inheritable cardiac conditions
it is recommended that patients consider whether adjust-
ments should be made with regard to specific job func-
tions, insurances and retirement plans and that this is
done before any clinical tests are performed [10].
Conclusions
To provide optimal patient care, irrespective of patient
age - physicians must be on the outlook for phenocopies
when identifying patients with possibly inheritable car-
diomyopathies. X chromosome-linked diseases are often
considered not to affect female carriers, but due to ran-
dom inactivation they may nonetheless develop discrete
and/or late presenting symptoms that require recogni-
tion and treatment.
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